MED6

Across TCGA pan-cancer cohorts, MED6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED6 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MED6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MED6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where MED6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.808	0.279	.001	37	view →
HNSC	DFS	Median	All	0.751	0.513	.004	13	view →
LSCC	DFS	Quartile	II,III,IV	0.945	0.423	.001	10	view →
CCRCC	OS	Median	All	0.626	0.985	.016	6	view →
PDAC	OS	Median	II,III,IV	0.789	0.935	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED6–LUAD (DFS)

Open the LUAD breakdown →